ViaCyte nabs $80 mln Series D
San Diego-based ViaCyte Inc, a privately-held clinical stage regenerative medicine company, has secured $80 million in Series D financing. The investors included Bain Capital Life Sciences, TPG and RA Capital Management.
30 November 2018•1 min read
